$75.29
+0.99
(+1.33%)
As of Oct 15, 2026, 12:34 AM EDT
Price history
Zoetis (ZTS) is trading up at $75.29 (+1.33%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Zoetis revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.89B | $5.31B | $5.83B | $6.26B | $6.67B | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Growth (year over year) | +2.6% | +8.6% | +9.8% | +7.5% | +6.6% | +16.5% | +3.9% | +5.7% | +8.3% | +2.3% |
| Gross profit | $3.22B | $3.53B | $3.91B | $4.27B | $4.62B | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B |
| Gross margin | 65.9% | 66.6% | 67.2% | 68.2% | 69.2% | 70.4% | 69.6% | 70.0% | 70.6% | 71.8% |
| Net income | $821.0M | $864.0M | $1.43B | $1.50B | $1.64B | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| Net margin | 16.8% | 16.3% | 24.5% | 24.0% | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
| EPS (diluted) | $1.65 | $1.75 | $2.93 | $3.11 | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
| Balance sheet | ||||||||||
| Cash and equivalents | $727.0M | $1.56B | $1.60B | $1.93B | $3.60B | $3.48B | $3.58B | $2.04B | $1.99B | $2.45B |
| Total assets | $7.65B | $8.59B | $10.8B | $11.5B | $13.6B | $13.9B | $14.9B | $14.3B | $14.2B | $15.5B |
| Total liabilities | $6.15B | $6.80B | $8.59B | $8.84B | $9.84B | $9.36B | $10.5B | $9.29B | $9.47B | $12.1B |
| Long-term debt | $4.47B | $4.95B | $6.44B | $5.95B | $6.59B | $6.59B | $6.55B | $6.56B | $5.22B | $9.04B |
| Shareholders' equity | $1.49B | $1.77B | $2.19B | $2.71B | $3.77B | $4.54B | $4.41B | $5.00B | $4.77B | $3.42B |
| Cash flow | ||||||||||
| Operating cash flow | $713.0M | $1.35B | $1.79B | $1.79B | $2.13B | $2.21B | $1.91B | $2.35B | $2.95B | $2.90B |
| Capital expenditure | $216.0M | $224.0M | $338.0M | $460.0M | $453.0M | $477.0M | $586.0M | $732.0M | $655.0M | $621.0M |
| Free cash flow | $497.0M | $1.12B | $1.45B | $1.33B | $1.67B | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B |
| Share buybacks | $300.0M | $500.0M | $698.0M | $626.0M | $250.0M | $743.0M | $1.59B | $1.09B | $1.86B | $3.23B |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.39B | $2.32B | $2.20B | $2.47B | $2.40B | $2.40B | $2.26B | $2.47B |
| Growth (year over year) | +11.0% | +4.7% | +0.4% | +4.8% | +0.5% | +3.4% | +2.9% | −0.2% |
| Gross profit | $1.69B | $1.61B | $1.58B | $1.81B | $1.72B | $1.69B | $1.62B | $1.79B |
| Gross margin | 70.6% | 69.5% | 71.9% | 73.2% | 71.5% | 70.7% | 71.7% | 72.7% |
| Net income | $682.0M | $581.0M | $602.0M | $726.0M | $721.0M | $624.0M | $601.0M | $691.0M |
| Net margin | 28.6% | 25.1% | 27.4% | 29.3% | 30.0% | 26.1% | 26.6% | 28.0% |
| EPS (diluted) | $1.50 | $1.29 | $1.34 | $1.63 | $1.63 | $1.42 | $1.42 | $1.65 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.71B | $1.99B | $1.72B | $1.44B | $2.08B | $2.45B | $1.94B | $1.48B |
| Total assets | $14.4B | $14.2B | $14.1B | $14.5B | $15.2B | $15.5B | $15.2B | $15.1B |
| Total liabilities | $9.12B | $9.47B | $9.44B | $9.50B | $9.76B | $12.1B | $11.9B | $11.9B |
| Long-term debt | $6.57B | $5.22B | $5.23B | $5.23B | $7.07B | $9.04B | $9.04B | $9.05B |
| Shareholders' equity | $5.23B | $4.77B | $4.66B | $4.98B | $5.40B | $3.42B | $3.23B | $3.15B |
| Cash flow | ||||||||
| Operating cash flow | $951.0M | $905.0M | $515.0M | $605.0M | $891.0M | $893.0M | $401.0M | $655.0M |
| Capital expenditure | $167.0M | $216.0M | $178.0M | $146.0M | $136.0M | $161.0M | $110.0M | $117.0M |
| Free cash flow | $784.0M | $689.0M | $337.0M | $459.0M | $755.0M | $732.0M | $291.0M | $538.0M |
| Share buybacks | $433.0M | $553.0M | $443.0M | $338.0M | $394.0M | $2.06B | $606.0M | $584.0M |
From Zoetis's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Zoetis
Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
- Headquarters
- Parsippany, New Jersey From SEC filings, Oct 2026
Recent News (20)
-
Zoetis at Morgan Stanley conference: pipeline offsets near-term pressure
Zoetis at Morgan Stanley conference: pipeline offsets near-term pressure
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Yahoo Finance
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Trefis
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Trefis
-
Zoetis (ZTS) Shares Drop After Earnings Revision
Zoetis (ZTS) Shares Drop After Earnings Revision
-
Is Zoetis Stock Underperforming the S&P 500?
Is Zoetis Stock Underperforming the S&P 500?
-
TD Cowen cuts Zoetis stock price target on clinic visit declines TD Cowen cuts Zoetis stock price target on clinic visit declines Investing.com
-
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
-
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
-
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
-
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
-
BNP Paribas Exane Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price BNP Paribas Exane Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price MarketBeat
-
Zoetis Stock: Is Wall Street Bullish or Bearish? Zoetis Stock: Is Wall Street Bullish or Bearish?
-
Zoetis (ZTS) Looked Like a Winner. What Went Wrong? Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
-
Zoetis Q2 Earnings Call Highlights Zoetis Q2 Earnings Call Highlights
-
Zoetis Inc. Q2 2026 Earnings Call Summary Zoetis Inc. Q2 2026 Earnings Call Summary
-
Zoetis stock falls on weak guidance despite earnings beat
Zoetis stock falls on weak guidance despite earnings beat
-
-
Zoetis (ZTS) Growth Weakens Amid Softening Pet Care Demand Zoetis (ZTS) Growth Weakens Amid Softening Pet Care Demand
More Health Care stocks
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services
- ZBH Zimmer Biomet
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology